Gilead Sciences, Inc. v. Merck & Co., Inc.

United States Court of Appeals for the Federal Circuit – 2018

“Patent rights cannot survive inequitable conduct.”

SHORT DESCRIPTION

Gilead Sciences, Inc. v. Merck & Co., Inc. is a landmark patent law decision emphasizing the doctrine of inequitable conduct. The case highlighted how improper behaviour during patent prosecution or related proceedings can render even valuable patents unenforceable. The judgment serves as a critical warning about ethical obligations in patent practice.

FACTS OF THE CASE

The dispute arose over patents covering groundbreaking antiviral drugs used in the treatment of hepatitis C. Merck alleged that Gilead’s products infringed its patents. However, during litigation, serious questions emerged regarding Merck’s conduct in relation to the patents.

Evidence revealed that a Merck patent attorney had engaged in misleading behaviour during interactions with Gilead, including providing incomplete disclosures and inconsistent representations. The conduct raised concerns about whether Merck had acted in good faith during patent-related dealings.

Gilead argued that Merck’s behaviour amounted to inequitable conduct, thereby rendering the patents unenforceable.

ISSUES INVOLVED

The central legal issue concerned whether Merck’s actions constituted inequitable conduct sufficient to invalidate enforcement of the patents.

COURT’S FINDINGS AND OBSERVATIONS

The Federal Circuit upheld the finding of inequitable conduct against Merck. The Court determined that the attorney’s actions involved misrepresentation and lack of candour, which are fundamentally incompatible with the integrity of the patent system.

The Court emphasized that patents are grounded in a duty of honesty and full disclosure. When a party breaches this duty, the consequence may be severe — unenforceability of the patent regardless of its technical merits.

This decision reinforced the principle that ethical violations can override substantive patent rights.

SUGGESTION / PRACTICAL TAKEAWAY

The ruling carries major implications for patent owners, attorneys, and corporations. Transparency, consistency, and good faith conduct are essential throughout patent prosecution and enforcement. Even commercially powerful patents can collapse if tainted by inequitable conduct.

Patent strategy must always align with ethical compliance.

JUDGMENT

Year: 2018

The Federal Circuit affirmed that inequitable conduct rendered Merck’s patents unenforceable.